Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients

Trial Profile

Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Dermatomyositis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms STIR
  • Most Recent Events

    • 25 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 29 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top